#1 Clinical Trials Search in Europe

Bi 706321

BI 706321 is an experimental drug currently being studied in clinical trials for its potential in treating Crohn’s disease. These trials aim to evaluate the safety, tolerability, and effectiveness of BI 706321 when used alone or in combination with other medications. The studies involve healthy volunteers and patients with Crohn’s disease, providing valuable insights into how the drug works in different populations and conditions.

Table of Contents

What is BI 706321?

BI 706321 is a new medication being developed to treat Crohn’s disease, a chronic inflammatory condition that affects the digestive tract[1]. Crohn’s disease can cause symptoms like abdominal pain, diarrhea, weight loss, and fatigue. BI 706321 is currently undergoing clinical trials to evaluate its effectiveness and safety in treating this condition.

How BI 706321 Works

While the exact mechanism of action is not explicitly stated in the provided information, BI 706321 is being studied as a potential treatment for Crohn’s disease. It is likely that this medication works by targeting specific components of the immune system involved in the inflammatory process of Crohn’s disease[1].

Clinical Trials

BI 706321 is being studied in several clinical trials to assess its effectiveness, safety, and how it interacts with other medications. Here are some key points about these trials:

  1. Phase IIa Trial for Crohn’s Disease: This study is testing BI 706321 in combination with ustekinumab, an existing medication for Crohn’s disease. The trial involves adults aged 18-75 years with moderate to severe Crohn’s disease[1].
    • Participants are divided into two groups: one receiving BI 706321 and ustekinumab, and the other receiving a placebo and ustekinumab.
    • The study lasts for about one year, with participants taking BI 706321 or placebo for 3 months, followed by 9 months of ustekinumab only.
    • Doctors perform colonoscopies to examine the bowel and compare results between the two groups.
  2. Safety and Tolerability Studies: Several trials are being conducted to test how well healthy individuals tolerate different doses of BI 706321[2][3]. These studies involve:
    • Testing single and multiple doses of BI 706321 in healthy Japanese and Chinese men.
    • Evaluating how the body processes the drug (pharmacokinetics) at different doses.
    • Assessing the safety profile of the medication.

Safety and Tolerability

The safety and tolerability of BI 706321 are being closely monitored in all clinical trials. Researchers are particularly interested in:

  • The percentage of participants experiencing drug-related side effects[2].
  • How the body processes the drug, including how quickly it reaches its maximum concentration in the blood and how long it stays in the body[3].
  • Any potential adverse events that may occur during treatment[1].
It’s important to note that as BI 706321 is still in the testing phase, all potential side effects may not yet be known.

Drug Interactions

Researchers are also studying how BI 706321 interacts with other medications. One study is specifically looking at how itraconazole, an antifungal medication, affects the levels of BI 706321 in the blood[4]. This information is crucial for understanding potential drug interactions and determining safe dosing guidelines for future use.

Future Prospects

While BI 706321 shows promise as a potential treatment for Crohn’s disease, it’s important to remember that it is still in the clinical trial phase. The ongoing studies will help determine:

  • The effectiveness of BI 706321 in reducing Crohn’s disease symptoms and promoting healing of the intestinal lining.
  • The optimal dosing regimen for the medication.
  • The long-term safety profile of BI 706321.
  • How well it works in combination with other Crohn’s disease treatments like ustekinumab.
If the clinical trials show positive results, BI 706321 could potentially become a new treatment option for people with Crohn’s disease in the future[1].

Aspect Details
Drug Name BI 706321
Purpose Treatment of Crohn’s disease
Trial Phases Phase I (healthy volunteers) and Phase IIa (Crohn’s disease patients)
Administration Oral tablets or capsules
Key Outcomes Measured Safety, tolerability, pharmacokinetics, endoscopic scores, clinical remission
Combination Therapy Studied with ustekinumab in Crohn’s disease patients
Study Duration Varies by trial, up to 1 year for Crohn’s disease study
Population Healthy volunteers and adults with moderate to severe Crohn’s disease

FAQ

  • What is BI 706321? BI 706321 is an experimental drug being developed to treat Crohn's disease. It is currently being studied in clinical trials to determine its safety, effectiveness, and how it interacts with other medications.
  • Who can participate in these clinical trials? The trials involve both healthy volunteers and patients with Crohn's disease. Some studies are specifically for healthy men, while others include adults aged 18-75 with moderate to severe Crohn's disease.
  • What are the main objectives of these clinical trials? The main objectives include investigating the safety and tolerability of BI 706321, studying how the body processes the drug (pharmacokinetics), and evaluating its effectiveness in treating Crohn's disease when combined with other medications like ustekinumab.
  • How is BI 706321 administered in these trials? BI 706321 is typically administered orally as tablets or capsules. In some trials, it may also be given as an oral solution. The dosage and frequency vary depending on the specific study design.
  • What are some of the outcomes being measured in these trials? The trials measure various outcomes, including the occurrence of drug-related side effects, changes in the concentration of the drug in the blood over time, improvements in Crohn's disease symptoms, and changes in endoscopic scores that assess the condition of the intestines.

Ongoing Clinical Trials on Bi 706321

  • Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Hungary Italy Poland Spain

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Placebo: A substance that looks like the real medicine but contains no active ingredient. It's used to compare the effects of the real drug against no treatment.
  • Endoscopic Score: A measure used to assess the severity of Crohn's disease by examining the inside of the intestines using a special camera.
  • Bioavailability: The amount of a drug that enters the bloodstream and is available to have an active effect in the body.
  • Crohn's Disease Activity Index (CDAI): A tool used to measure the severity of Crohn's disease symptoms, with lower scores indicating less severe disease.
  • C-Reactive Protein (CRP): A substance in the blood that increases when there's inflammation in the body. It's used to monitor disease activity in Crohn's disease.
  • Faecal Calprotectin (FCP): A substance found in stool samples that can indicate inflammation in the intestines. It's used to assess disease activity in Crohn's disease.

References

  1. https://clinicaltrials.eu/trial/study-on-bi-706321-and-ustekinumab-for-patients-with-moderate-to-severe-crohns-disease/
  2. https://clinicaltrials.gov/study/NCT05183360
  3. https://clinicaltrials.gov/study/NCT03971695
  4. https://clinicaltrials.gov/study/NCT04714073